Medium chain length polyhydroxyalkanoates, promising new biomedical materials for the future

Medium chain length polyhydroxyalkanoates, mcl-PHAs (C6–C14 carbon atoms), are polyesters of hydroxyalkanoates produced mainly by fluorescent Pseudomonads under unbalanced growth conditions. These mcl-PHAs which can be produced using renewable resources are biocompatible, biodegradable and thermoprocessable. They have low crystallinity, low glass transition temperature, low tensile strength and high elongation to break, making them elastomeric polymers. Mcl-PHAs and their copolymers are suitable for a range of biomedical applications where flexible biomaterials are required, such as heart valves and other cardiovascular applications as well as matrices for controlled drug delivery. Mcl-PHAs are more structurally diverse than short chain length PHAs and hence can be more readily tailored for specific applications. Composites have also been fabricated using mcl-PHAs and their copolymers, such as poly (3-hydroxyoctanoate) [P(3HO)] combined with single walled carbon nanotubes and poly(3-hydroxbutyrate-co-3-hydroxyhexanoate) [P(3HB-co-3HHx)] combined with hydroxyapatite. Because of these attractive properties of biodegradability, biocompatibility and tailorability, Mcl-PHAs and their composites are being increasingly used for biomedical applications. However, studies remain limited mainly to P(3HO) and the copolymer P(3HB-co-3HHx), which are the only mcl-PHAs available in large quantities. In this review we have consolidated current knowledge on the properties and biomedical applications of these elastomeric mcl-PHAs, their copolymers and their composites.